Coal tar with dithranol and salicylic acid
A topical preparation combining coal tar, dithranol (anthralin) and salicylic acid, used for chronic plaque psoriasis, with each component targeting a different aspect of the psoriatic plaque.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Dithranol is an antiproliferative agent that inhibits keratinocyte hyperproliferation, coal tar adds anti-inflammatory and antiscaling action, and salicylic acid is a keratolytic that removes scale and enhances penetration of the active agents.
Prescribing in practice
- Dithranol is a potent irritant that burns and stains normal skin, so it must be applied carefully to plaques only, kept off the face, flexures and genitals, and removed as directed; it stains skin purple-brown and permanently stains clothing, bathware and hair.
- Coal tar increases photosensitivity, so protect treated skin from sunlight and use caution with phototherapy.
- Avoid use on acute, inflamed, pustular or broken skin where irritation is likely.
Monitoring
No laboratory monitoring is needed; review the plaques for response and the surrounding normal skin for dithranol-induced burning or staining.
Counselling the patient
- Apply precisely to the psoriasis plaques only, avoid healthy skin, and wash your hands thoroughly afterwards.
- Expect staining of skin, hair, fabrics and the bath, and a tar smell.
- Stop and seek advice if normal skin becomes burnt, very red or sore.
Evidence & guidelines
Dithranol and coal tar preparations are long-established topical treatments for stable chronic plaque psoriasis and are included in NICE psoriasis guidance.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- PASI — Psoriasis Area and Severity Index · Diagnosis
- DLQI — Dermatology Life Quality Index · Diagnosis
- PASI Score (Psoriasis Area and Severity Index) · Psoriasis
- DLQI (Dermatology Life Quality Index) · Quality of Life
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD